Literature DB >> 16681555

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

K G M M Alberti1, P Zimmet, J Shaw.   

Abstract

AIMS: To establish a unified working diagnostic tool for the metabolic syndrome (MetS) that is convenient to use in clinical practice and that can be used world-wide so that data from different countries can be compared. An additional aim was to highlight areas where more research into the MetS is needed. PARTICIPANTS: The International Diabetes Federation (IDF) convened a workshop held 12-14 May 2004 in London, UK. The 21 participants included experts in the fields of diabetes, public health, epidemiology, lipidology, genetics, metabolism, nutrition and cardiology. There were participants from each of the five continents as well as from the World Health Organization (WHO) and the National Cholesterol Education Program-Third Adult Treatment Panel (ATP III). The workshop was sponsored by an educational grant from AstraZeneca Pharmaceuticals. CONSENSUS PROCESS: The consensus statement emerged following detailed discussions at the IDF workshop. After the workshop, a writing group produced a consensus statement which was reviewed and approved by all participants.
CONCLUSIONS: The IDF has produced a new set of criteria for use both epidemiologically and in clinical practice world-wide with the aim of identifying people with the MetS to clarify the nature of the syndrome and to focus therapeutic strategies to reduce the long-term risk of cardiovascular disease. Guidance is included on how to compensate for differences in waist circumference and in regional adipose tissue distribution between different populations. The IDF has also produced recommendations for additional criteria that should be included when studying the MetS for research purposes. Finally, the IDF has identified areas where more studies are currently needed; these include research into the aetiology of the syndrome.

Entities:  

Mesh:

Year:  2006        PMID: 16681555     DOI: 10.1111/j.1464-5491.2006.01858.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  1618 in total

1.  Determination of minimum alveolar concentration for isoflurane and sevoflurane in a rodent model of human metabolic syndrome.

Authors:  Dinesh Pal; Meredith E Walton; William J Lipinski; Lauren G Koch; Ralph Lydic; Steve L Britton; George A Mashour
Journal:  Anesth Analg       Date:  2011-12-13       Impact factor: 5.108

Review 2.  Effects of dairy protein and fat on the metabolic syndrome and type 2 diabetes.

Authors:  Ann Bjørnshave; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2014-08-10

3.  Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome.

Authors:  Francesco Angelico; Lorenzo Loffredo; Pasquale Pignatelli; Teresa Augelletti; Roberto Carnevale; Antonio Pacella; Fabiana Albanese; Ilaria Mancini; Serena Di Santo; Maria Del Ben; Francesco Violi
Journal:  Intern Emerg Med       Date:  2011-04-22       Impact factor: 3.397

Review 4.  Cardiovascular and Metabolic Complications - Diagnosis and Management in Obese Children.

Authors:  Naval K Vikram
Journal:  Indian J Pediatr       Date:  2017-12-08       Impact factor: 1.967

5.  Effect of alpha-tocopherol and beta-carotene supplementation on the incidence of type 2 diabetes.

Authors:  M Kataja-Tuomola; J R Sundell; S Männistö; M J Virtanen; J Kontto; D Albanes; J Virtamo
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

Review 6.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

7.  Levels of 4-1BB transcripts and soluble 4-1BB protein are elevated in the adipose tissue of human obese subjects and are associated with inflammatory and metabolic parameters.

Authors:  T H Tu; C-S Kim; J-H Kang; I S Nam-Goong; C W Nam; E S Kim; Y I Kim; J I Choi; T Kawada; T Goto; T Park; J H Yoon Park; M-S Choi; R Yu
Journal:  Int J Obes (Lond)       Date:  2013-11-27       Impact factor: 5.095

8.  Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease.

Authors:  V M Herrera; J P Casas; J J Miranda; P Perel; R Pichardo; A González; J R Sanchez; C Ferreccio; X Aguilera; E Silva; M Oróstegui; L F Gómez; J A Chirinos; J Medina-Lezama; C M Pérez; E Suárez; A P Ortiz; L Rosero; N Schapochnik; Z Ortiz; D Ferrante; M Diaz; L E Bautista
Journal:  Int J Obes (Lond)       Date:  2009-02-24       Impact factor: 5.095

9.  Comparison of coronary heart disease risk among four diagnostic definitions of metabolic syndrome.

Authors:  T Suzuki; Z Zeng; B Zhao; Z Wei; M Tanabe; T Shimbo; H Kajio; N Kato; M Naruse
Journal:  J Endocrinol Invest       Date:  2016-08-29       Impact factor: 4.256

10.  Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome.

Authors:  Elizabeth Stein; Harvey Kushner; Samuel Gidding; Bonita Falkner
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.